Convergence Pharmaceuticals Limited

Glaxo Group Limited

Roberto Profeta

Giuseppe Alvaro

Markus Bergauer

Riccardo Giovannini

David Amantini

Francesca Bonetti

Daniele Andreotti

David Norton

Simon Edward Ward

Simone Spada

Helen Susanne Price

The invention relates to novel piperazine compounds of formula (I): to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.

Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers

Compounds of formula (I), pharmaceutical compositions thereof, and methods for treatment using the same. 

Compounds

The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. Methods of treating epilepsy in a mammal are also provided.

Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide

The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. Methods of treating and moderating one or more bipolar disorders in a mammal are also provided.

Methods of treating bipolar disorders

The invention relates to quaternary &#x3b1;-aminocarboxyamide derivatives of formula (I), wherein R, R, R, R, R, R, X, q and n are as defined in claim, for treating diseases and conditions mediated by modulation of voltage-gated sodium channels. 

The invention provides a compound of formula (I), pharmaceutical compositions thereof, and methods of treatment using the same. 

Growing community of inventors

Verona, Italy

Roberto Profeta